Rani Therapeutics Holdings (RANI) Cash & Equivalents (2020 - 2026)

Rani Therapeutics Holdings has reported Cash & Equivalents for 7 years, with the latest figure at $53.4 million in Q2 2026.

• On a quarterly basis, Cash & Equivalents rose 422.71% year-over-year to $53.4 million in Q2 2026; TTM through Jun 2026 was $53.4 million, a 422.71% increase from a year earlier, with the FY2025 full-year figure at $18.6 million, up 394.9% from the prior year.
• Cash & Equivalents was $53.4 million for Q2 2026 at Rani Therapeutics Holdings, up from $43.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $107.8 million in Q1 2022, with the low at $3.8 million in Q4 2024.
• Average Cash & Equivalents over 5 years is $25.3 million, with a median of $10.2 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2026: Cash & Equivalents slumped 92.23% in 2023, then surged 422.71% in 2026.
• Over 5 years, Cash & Equivalents stood at $27.0 million in 2022, then slumped by 78.29% to $5.9 million in 2023, then sank by 35.85% to $3.8 million in 2024, then soared by 394.9% to $18.6 million in 2025, then soared by 186.82% to $53.4 million in 2026.
• The last three Cash & Equivalents figures came in at $53.4 million (Q2 2026), $43.4 million (Q1 2026), and $18.6 million (Q4 2025), per Business Quant data.